Order Now, Ships Today
One-time
| Quantity | Discount | Discounted price |
| 3 - 4 | 5% | - |
| 5 - 6 | 7% | - |
| 7 - 8 | 9% | - |
| 9 + | 11% | - |
These products are for laboratory research only and not intended for medical use. They are not FDA-approved to diagnose, treat, cure, or prevent any disease. By purchasing, you certify they will be used solely for research and not for human or animal consumption.
Tirzepatide is a synthetic dual-receptor agonist used in laboratory research involving GLP-1 and GIP receptor systems. Experimental investigations examine receptor activation, downstream signaling, pathway interaction and metabolic signaling responses under controlled research conditions.
This research peptide is tested for 99%+ purity. COA: Tirzepatide (5mg / 60mg)
Products from Elite Miami Peptides do not include usage instructions, as they are strictly for in vitro research and prohibited by law for human or animal use. Misuse or unlawful application will result in permanent denial of service.
Each vial contains the quantity of lyophilized research material indicated on the product label. Refer to the lot-specific Certificate of Analysis for identity and purity information.
Yes. All peptides are supplied in lyophilized powder form and do not come reconstituted. Any extra materials required for research, such as solvents or diluents, must be obtained separately.
When stored as a dry powder, peptides remain stable for up to 2 years.
Once reconstituted, the solution should be kept refrigerated and is typically stable for up to 2 months under proper storage conditions.
Tirzepatide is a synthetic dual-agonist peptide that simultaneously activates both GLP-1 and GIP receptors — two key hormonal systems involved in metabolic regulation. By combining these pathways, Tirzepatide has been studied for its potential to enhance insulin sensitivity, improve glucose regulation, and influence lipid metabolism in controlled research models. This dual action has made it a leading candidate for investigating complex metabolic mechanisms.
Tirzepatide allows researchers to investigate how simultaneous activation of GLP-1 and GIP receptor systems affects downstream cellular and metabolic signaling pathways.
⚠️ Disclaimer: this product is not approved for medical use and is not intended to diagnose, treat, or prevent any disease. All information provided is for educational and research purposes only, and this product must never be used in humans or animals.
The concept of Tirzepatide stems from incretin research, which began with the discovery of GLP-1 and GIP as key regulators of glucose homeostasis. After the development of GLP-1 receptor agonists demonstrated the utility of targeting incretin biology, researchers expanded into dual agonist strategies. Tirzepatide was synthesized in the 2010s as a novel investigational compound with balanced activity at both GIP and GLP-1 receptors, designed to explore synergistic signaling in metabolic regulation and endocrine research. Coskun T. et al. (2018).
CAS #: 2023788-19-2 Molecular Formula: C₂₂₅H₃₆₀N₆₂O₈₅ Molecular Weight: 4813.5 g/mol PubChem ID: 137346133
Tirzepatide has been investigated in metabolic and cellular models, showing relevance in the following areas: Metabolic: glucose regulation, lipid metabolism, energy balance. Endocrine: GLP-1 and GIP receptor signaling pathways. Molecular: insulin secretion, beta-cell response mechanisms. Cellular: receptor binding, cAMP signaling, hormone modulation. Collectively, research findings indicate Tirzepatide’s experimental potential in studying complex metabolic feedback systems and dual-receptor modulation for insulin-related processes.
In simple terms, Tirzepatide is being studied as a peptide that can “speak” to two metabolic hormone systems at once — helping researchers explore how it may influence energy use, appetite, and glucose balance. While results in lab studies are promising, Tirzepatide is not approved for human or animal use and should only be used in research environments by qualified professionals.
Frias J.P., et al. (2021). Efficacy and activity of dual GLP-1/GIP receptor agonists in metabolic research. Coskun T., et al. (2018). Mechanisms of dual incretin peptide activity in glucose regulation. Campbell J.E., et al. (2020). Dual receptor signaling and energy balance modulation studies.
5-Amino-1mq
Our specialists respond within minutes to any order or product inquiry.
These products are for laboratory research only and not intended for medical use. They are not FDA-approved to diagnose, treat, cure, or prevent any disease. By purchasing, you certify they will be used solely for research and not for human or animal consumption.
All compounds from Elite Miami Peptides are intended strictly for laboratory research purposes.
They are not for human use, consumption, or therapeutic applications.
Products are supplied exclusively to qualified professionals working in compliance with all applicable laws and regulations.
